SR One Capital Management, which spun out of GlaxoSmithKline, has closed on more than $600 million, substantially exceeding its target of $500 million, for its second venture capital fund.

The trans-Atlantic biotech venture capital firm said in a press release that Fund II is the second fund since SR One spun out from GlaxoSmithKline (GSK) in 2020 to form a full